RAAIS 2025 - Max Jaderberg, Chief AI Officer at Isomorphic Labs

Isomorphic Labs leverages machine learning and reinforcement learning to revolutionize drug design, aiming to solve human disease by treating biology as a complex, solvable system. By creating AI analogues of the real world, the company moves beyond traditional, slow experimental methods toward in silico scientific discovery. The development of AlphaFold3 marks a significant milestone, enabling accurate structural prediction of biomolecular complexes—including proteins, DNA, and small molecules—by modeling atomic interactions. These generative models and design agents significantly increase hit rates in drug discovery, allowing for the rational design of both small-molecule drugs and large-molecule therapeutics like antibodies. This paradigm shift enables researchers to simulate hypotheses in parallel, effectively turning drug discovery into a high-speed, computer-driven process that produces real-world results, ultimately aiming to replicate "move 37" moments of creative invention across the broader scientific landscape.